SABCS 2025 | The benefits of intrathecal administration of dendritic cells for breast cancer

Yeah, well, I think administering it directly allows you to overcome that problem of being a sanctuary site so you can get it right in there. And I think that analysis we talked about shows that it turns on these immune cells specifically that are helpful in fighting tumor cells and maybe, but the B cells maybe make antibodies, which would be long-term protection. So that’s pretty exciting. And in mice, we find that if we cure mice, you know, and mice are mice, not people, but if you cure mice with this treatment, that at least half the time you, and when you try to put tumor cells back in the spinal fluid, they won’t grow. And by curing mice in a different way, you know, 100% of the time the tumor cells won’t grow again. So I think that’s the long-term goal is to kind of treat the stuff up here and we might have to treat any little tiny tumors or lymph nodes that might be there to confer resistance. But this is all speculation at the moment. But it just really helps because it helps think about stuff in a new way. Oh, and for example, there’s also some bad cells in there. So I only talked about the immune cells that turn on immune responses, but there’s bad cells like myeloid cells and everybody knows they do, they get in the way, they inhibit all the inflammation and stop tumor cell killing. So it suggests obvious strategies that we could give an antibody to, you know, kill the bad cells, if you will, the myeloid cells. So it’s a lot, it’s very exciting and very gratifying, you know.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.